Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. September 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics to Present at Upcoming Investor Conferences

FLEMINGTON, N.J., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
14. August 2014 16:49 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update

FLEMINGTON, N.J., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
18. Juli 2014 16:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer

FLEMINGTON, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
29. Mai 2014 16:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

FLEMINGTON, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
15. Mai 2014 16:40 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Reports First Quarter 2014 Financial and Business Update

FLEMINGTON, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
14. Mai 2014 17:00 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men's and Women's Cancers at 2014 ASCO Annual Meeting

Studies to determine recommended Phase II dose and safety profile of lead compound Will analyze relationship of biomarker to any anti-tumor activity observed FLEMINGTON, N.J., May 14, 2014...
05. Mai 2014 08:30 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Announces Clinical Abstracts Accepted at 2014 ASCO Annual Meeting

FLEMINGTON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced...
07. April 2014 10:42 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer

FLEMINGTON, N.J., April 7, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
01. April 2014 09:10 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones

FLEMINGTON, N.J., April 1, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
26. März 2014 08:45 ET | Quelle: Arno Therapeutics Inc.

Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014

FLEMINGTON, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Vorherige Seite

Nächste Seite